Citius Oncology (CTOR) Enterprise Value (2022 - 2026)

Citius Oncology (CTOR) has reported Enterprise Value for 5 consecutive years, with $52.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value fell 83.24% year-over-year to $52.2 million in Q2 2026; TTM through Jun 2026 was $52.2 million, a 83.24% decrease from a year earlier, with the FY2025 full-year figure at $165.6 million, up 66.51% from the prior year.
• Enterprise Value was $52.2 million for Q2 2026 at Citius Oncology, down from $55.0 million in the prior quarter.
• Over five years, Enterprise Value peaked at $738.4 million in Q4 2023 and troughed at $32.3 million in Q4 2022.
• A 5-year average of $139.5 million and a median of $82.3 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 2186.38% in 2023 and sank 88.86% in 2024, its largest moves.
• Over 5 years, Enterprise Value stood at $32.3 million in 2022, then surged by 2186.38% to $738.4 million in 2023, then slumped by 88.86% to $82.3 million in 2024, then slipped by 5.81% to $77.5 million in 2025, then tumbled by 32.67% to $52.2 million in 2026.
• The last three Enterprise Value figures came in at $52.2 million (Q2 2026), $55.0 million (Q1 2026), and $77.5 million (Q4 2025), per Business Quant data.